Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:JANX NASDAQ:MRUS NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$81.99+1.2%$47.06$4.77▼$82.51$6.12B0.581.04 million shs592,352 shsJANXJanux Therapeutics$22.86+0.6%$24.50$21.97▼$71.71$1.37B2.84787,388 shs904,571 shsMRUSMerus$66.30+0.7%$61.76$33.19▼$69.20$4.98B1.19575,232 shs704,741 shsNUVLNuvalent$76.90+0.4%$78.55$55.53▼$113.51$5.52B1.29406,504 shs565,769 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+4.61%+12.64%+946.90%+537.53%JANXJanux Therapeutics0.00%-1.26%-3.57%-10.66%-51.64%MRUSMerus0.00%+0.15%+0.43%+5.48%+29.12%NUVLNuvalent0.00%+3.42%-1.52%-2.05%-10.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXAbivax3.1013 of 5 stars3.65.00.00.02.30.80.6JANXJanux Therapeutics3.2395 of 5 stars3.53.00.00.03.63.30.0MRUSMerus2.7774 of 5 stars3.53.00.00.02.82.50.0NUVLNuvalent3.2385 of 5 stars4.50.00.00.03.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.13Buy$92.3312.62% UpsideJANXJanux Therapeutics 3.08Buy$86.90280.14% UpsideMRUSMerus 3.08Buy$88.7533.86% UpsideNUVLNuvalent 3.09Buy$120.8057.09% UpsideCurrent Analyst Ratings BreakdownLatest JANX, ABVX, NUVL, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025MRUSMerusIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$90.008/25/2025MRUSMerusAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$90.008/19/2025NUVLNuvalentPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$112.008/18/2025JANXJanux TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.008/6/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/6/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$97.00 ➝ $96.007/29/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $112.007/23/2025ABVXAbivaxLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$74.007/23/2025ABVXAbivaxLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$45.00 ➝ $101.007/23/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$42.00 ➝ $70.007/23/2025ABVXAbivaxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $101.00(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AJANXJanux Therapeutics$10.59M129.71N/AN/A$16.48 per share1.39MRUSMerus$36.13M138.78N/AN/A$11.13 per share5.96NUVLNuvalentN/AN/AN/AN/A$13.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/AJANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)Latest JANX, ABVX, NUVL, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25JANXJanux TherapeuticsN/A47.0347.03MRUSMerusN/A8.398.39NUVLNuvalentN/A13.5713.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%JANXJanux Therapeutics75.39%MRUSMerus96.14%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AJANXJanux Therapeutics29.40%MRUSMerus3.70%NUVLNuvalent10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.57 millionN/ANot OptionableJANXJanux Therapeutics3060.09 million42.43 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableJANX, ABVX, NUVL, and MRUS HeadlinesRecent News About These CompaniesParadigm Biocapital Advisors LP Trims Stock Position in Nuvalent, Inc. $NUVLSeptember 2 at 7:09 AM | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Northern Trust CorpSeptember 2 at 3:57 AM | marketbeat.comPiper Sandler Initiates Nuvalent (NUVL) Amid Key Cancer Drug CatalystsSeptember 2 at 2:10 AM | insidermonkey.comNuvalent, Inc. $NUVL Holdings Lowered by Rafferty Asset Management LLCSeptember 1 at 4:43 AM | marketbeat.comBrokerages Set Nuvalent, Inc. (NASDAQ:NUVL) Target Price at $120.80September 1 at 2:15 AM | americanbankingnews.comDriehaus Capital Management LLC Has $37.67 Million Stock Position in Nuvalent, Inc. $NUVLAugust 31 at 7:14 AM | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Buy" from AnalystsAugust 31 at 2:11 AM | marketbeat.comNuvalent, Inc. $NUVL Shares Bought by Tema Etfs LLCAugust 30 at 8:19 AM | marketbeat.comTri Locum Partners LP Makes New $6.80 Million Investment in Nuvalent, Inc. $NUVLAugust 30 at 8:04 AM | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Jump Financial LLCAugust 30 at 5:00 AM | marketbeat.comNuvalent, Inc. $NUVL Holdings Raised by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comNuvalent to Participate in the Cantor Global Healthcare Conference 2025August 28, 2025 | prnewswire.comPrice T Rowe Associates Inc. MD Raises Stock Position in Nuvalent, Inc. $NUVLAugust 28, 2025 | marketbeat.comNuveen LLC Buys Shares of 83,976 Nuvalent, Inc. $NUVLAugust 28, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Makes New $31.97 Million Investment in Nuvalent, Inc. $NUVLAugust 26, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by American Century Companies Inc.August 26, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Purchased by Wellington Management Group LLPAugust 24, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Deutsche Bank AGAugust 24, 2025 | marketbeat.comNuvalent, Inc. $NUVL Shares Sold by Charles Schwab Investment Management Inc.August 24, 2025 | marketbeat.comCandriam S.C.A. Sells 13,966 Shares of Nuvalent, Inc. $NUVLAugust 23, 2025 | marketbeat.comAberdeen Group plc Acquires 19,987 Shares of Nuvalent, Inc. $NUVLAugust 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJANX, ABVX, NUVL, and MRUS Company DescriptionsAbivax NASDAQ:ABVX$81.99 +0.96 (+1.18%) Closing price 04:00 PM EasternExtended Trading$81.95 -0.04 (-0.05%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Janux Therapeutics NASDAQ:JANX$22.86 +0.14 (+0.62%) Closing price 04:00 PM EasternExtended Trading$22.84 -0.02 (-0.09%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Merus NASDAQ:MRUS$66.30 +0.46 (+0.70%) Closing price 04:00 PM EasternExtended Trading$66.34 +0.05 (+0.07%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Nuvalent NASDAQ:NUVL$76.90 +0.32 (+0.42%) Closing price 04:00 PM EasternExtended Trading$77.47 +0.57 (+0.74%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
